Teva launches generic Lomedia 24 Fe birth control
BY DSN STAFF
JERUSALEM — Teva on Friday announced that it would be rolling out Junel Fe 24 (norethindrone acetate and ethinyl estradiol tablets USP, 1 mg/20 mcg and ferrous fulmate tablets, 75 mg), a generic version of Lomedia 24 Fe birth control bills.
With the addition of Junel Fe 24, Teva’s line of generic contraceptives expands to nearly 30 offerings.
Walgreens Boots Alliance chief information officer steps down
BY DSN STAFF
DEERFIELD, Ill. – Walgreens Boots Alliance on Friday announced that Tim Theriault, EVP, global chief information officer, will step down, effective June 1, for personal reasons. Theriault will continue to serve as a consultant to the company and as a senior advisor to executive vice chairman and acting CEO Stefano Pessina on a range of issues, including cyber security.
Anthony Roberts, who had served as SVP, international CIO, will now assume the role of Walgreens Boots Alliance SVP, global CIO.
“Tim has played a critically important role over the past six years leading Walgreens IT transformation, and advancing and integrating the Walgreens Boots Alliance technology teams and infrastructure since the merger of Walgreens and Alliance Boots last December," Pessina said. "We are grateful for all that Tim has done and for continuing as a consultant and a senior advisor to me as we pursue new global frontiers in IT to serve customers, patients and partners.”
Roberts brings extensive experience as an IT professional to his new role, having worked for international companies throughout his career including PepsiCo and UPS. In addition, he has led the transformation of IT across Alliance Boots and most recently co-led the integration office in preparation for the merger of Walgreens and Alliance Boots.
Roxane Labs makes recently approved IBS treatment available to ship
COLUMBUS, Ohio — On Thursday Roxane Laboratories announced that its alosetron hydrochloride tablets — a generic version of irritable bowel syndrome treatment Lotronex — was available in 0.5- and 1-mg strength.
The U.S. Food and Drug Administration approved Roxane’s abbreviated new drug application for the medication on May 4, making an approximately $86 million annual market available to the company.
The news of the availability of Roxane’s IBS drug comes the same day that the FDA approved two new brand-name IBS treatments, Patheon Pharmaceuticals’ Viberzi and Salix Pharmaceuticals’ Xifaxan.
Loading Post Please Wait...